Pharmaceuticals Study shows potential of psilocybin as an antidepressant compared to non-psychoactive drugs Last updated: May 13, 2024 11:23 am By bexib 0 Min Read Share SHARE Study results showed that psilocybin may reduce symptoms of depression, with significant support for response and remission rates. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article Glenn Loury Tells All – Econlib Next Article Competition Bureau finds ‘serious competitive concerns’ in Bunge’s proposed acquisition of Vitera – RealAgriculture Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Weekly new unemployment claims fall to 227,000 Economy New home sales in September rose to an annual rate of 738,000 units Economy Price control with fixed supply Economy Chinese car companies are doubling down on offshore manufacturing Manufacturing